Health policy has quietly become a stock-moving variable in 2026, and the figures are significant enough to matter. Approximately 2.6 million Americans discontinued ACA marketplace coverage this year after increased pandemic-era subsidies ended at the end of 2025, with health policy experts predicting that total enrollment would decrease to between 16.5 million and 17.5 million by year-end. Meanwhile, the Urban Institute has projected that 4.8 million more people will be uninsured in 2026 as a direct consequence of the lapsed subsidies, with certain HealthCare.gov-reliant states witnessing enrollment losses of 20% or more.
Whether this translates into fewer elective medical treatments is now a hotly debated topic in the healthcare industry, with Intuitive Surgical, Inc. (NASDAQ:ISRG) emerging as the evident casualty. The company's shares plunged more than 12% before the bell on July 17, despite Intuitive maintaining its global procedure-growth prediction for its da Vinci surgical robots. Instead, the selloff was driven by the company's own admission that changes in insurance coverage could impact demand.
US da Vinci procedure growth slowed to roughly 12% in the second quarter, down from where Intuitive Surgical, Inc. (NASDAQ:ISRG) expected to be at the beginning of the year, with a focus on surgeries that patients may defer. On the July 16 call, CEO David Rosa told ******* ysts that customer conversations indicated that fluctuating patient coverage and premium dynamics affect "when patients seek care," as opposed to if they seek it at all.
That reaction came at an awkward time, as a highly public disagreement was already taking place in the sector. Abbott, a major medical device and diagnostics manufacturer, had argued recently that blaming industry-wide procedure weakness on ACA disenrollment was a "flawed ******* umption." HCA Healthcare, the largest for-profit hospital operator in the United States, took the opposite stance, warning earlier of lower surgical demand and an increase in uninsured patients when pandemic-era subsidies expired.
Intuitive's own results now appear to support the HCA side of the argument, at least in procedures when patients can choose to delay. Stifel's response immediately reflected the tension: the firm reduced its price objective to $550 from $670 on July 17 while keeping a Buy rating on the company's shares, despite Intuitive Surgical, Inc. (NASDAQ:ISRG) exceeding expectations in revenue, earnings, system placements, and procedure growth in the same quarter. Both US procedure and installed-base growth have slowed since the 2020-2021 COVID era, with management blaming the slowdown on ACA disenrollment and the basic law of large numbers as the installed base matures.
#NASDAQ #Growth #healthcare
Whether this translates into fewer elective medical treatments is now a hotly debated topic in the healthcare industry, with Intuitive Surgical, Inc. (NASDAQ:ISRG) emerging as the evident casualty. The company's shares plunged more than 12% before the bell on July 17, despite Intuitive maintaining its global procedure-growth prediction for its da Vinci surgical robots. Instead, the selloff was driven by the company's own admission that changes in insurance coverage could impact demand.
US da Vinci procedure growth slowed to roughly 12% in the second quarter, down from where Intuitive Surgical, Inc. (NASDAQ:ISRG) expected to be at the beginning of the year, with a focus on surgeries that patients may defer. On the July 16 call, CEO David Rosa told ******* ysts that customer conversations indicated that fluctuating patient coverage and premium dynamics affect "when patients seek care," as opposed to if they seek it at all.
That reaction came at an awkward time, as a highly public disagreement was already taking place in the sector. Abbott, a major medical device and diagnostics manufacturer, had argued recently that blaming industry-wide procedure weakness on ACA disenrollment was a "flawed ******* umption." HCA Healthcare, the largest for-profit hospital operator in the United States, took the opposite stance, warning earlier of lower surgical demand and an increase in uninsured patients when pandemic-era subsidies expired.
Intuitive's own results now appear to support the HCA side of the argument, at least in procedures when patients can choose to delay. Stifel's response immediately reflected the tension: the firm reduced its price objective to $550 from $670 on July 17 while keeping a Buy rating on the company's shares, despite Intuitive Surgical, Inc. (NASDAQ:ISRG) exceeding expectations in revenue, earnings, system placements, and procedure growth in the same quarter. Both US procedure and installed-base growth have slowed since the 2020-2021 COVID era, with management blaming the slowdown on ACA disenrollment and the basic law of large numbers as the installed base matures.
#NASDAQ #Growth #healthcare
3 months ago
